Changes to Biohit Oyj’s management: Change of R&D Director

Publishing on December 15, 2022 at 2:00 pm local time (EEST)

Biohit Oyj’s R&D Director PhD and Associate Professor Minna Mäki has resigned. Current Head of Technical Product Management Panu Hendolin has been appointed to new R&D Director.

Hendolin has worked at Biohit as R&D and Production Director in 2007-2008, as well as 2012-2017, and he returned to the company in February 2022. In the meanwhile, Hendolin worked as Production Director at United Medix Laboratories Oy and Chief Technology Officer at Sulapac Oy. Hendolin has the degree of Ph.D. in molecular medicine.

CEO Jussi Hahtela: “I want to thank Minna Mäki for her contribution and significant role in R&D and in regulatory affairs. I wish her all the best in her future endeavors.”

Additional information: 
Jussi Hahtela, CEO, Biohit Oyj, tel. +358 50 383 5948

investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com